Last reviewed · How we verify

Solution for Injection in Sham Block

Wake Forest University Health Sciences · Phase 3 active Small molecule Under review

Solution for Injection in Sham Block is a Small molecule drug developed by Wake Forest University Health Sciences. It is currently in Phase 3 development for Treatment of various conditions in clinical trials. Also known as: Lidocaine.

This drug is a solution for injection in a sham block, which is used to treat various conditions.

A solution for injection in a sham block is Bupivacaine-Epinephrine 0.5%-1:200,000 Injectable Solution. This solution has been studied in clinical trials for various conditions, including analgesia, pain, and postoperative pain, often in combination with other interventions such as periarticular injection or continuous femoral nerve block.

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameSolution for Injection in Sham Block
Also known asLidocaine
SponsorWake Forest University Health Sciences
ModalitySmall molecule
PhasePhase 3

Mechanism of action

The exact mechanism of this drug is unknown, but it is used as a control in clinical trials to compare the effects of the active treatment.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Solution for Injection in Sham Block

What is Solution for Injection in Sham Block?

Solution for Injection in Sham Block is a Small molecule drug developed by Wake Forest University Health Sciences, indicated for Treatment of various conditions in clinical trials.

How does Solution for Injection in Sham Block work?

This drug is a solution for injection in a sham block, which is used to treat various conditions.

What is Solution for Injection in Sham Block used for?

Solution for Injection in Sham Block is indicated for Treatment of various conditions in clinical trials.

Who makes Solution for Injection in Sham Block?

Solution for Injection in Sham Block is developed by Wake Forest University Health Sciences (see full Wake Forest University Health Sciences pipeline at /company/wake-forest-university-health-sciences).

Is Solution for Injection in Sham Block also known as anything else?

Solution for Injection in Sham Block is also known as Lidocaine.

What development phase is Solution for Injection in Sham Block in?

Solution for Injection in Sham Block is in Phase 3.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing